Liquidia (NASDAQ:LQDA - Free Report) had its price target lifted by Scotiabank from $34.00 to $36.00 in a report released on Monday morning, Marketbeat Ratings reports. Scotiabank currently has a sector outperform rating on the stock.
Several other analysts also recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright restated a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Liquidia has an average rating of "Buy" and a consensus price target of $26.88.
View Our Latest Report on Liquidia
Liquidia Stock Performance
NASDAQ:LQDA traded down $0.01 during mid-day trading on Monday, hitting $15.53. The stock had a trading volume of 1,156,745 shares, compared to its average volume of 998,556. The company's 50 day simple moving average is $14.24 and its 200 day simple moving average is $13.09. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -9.53 and a beta of 0.24. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.81.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. As a group, equities analysts forecast that Liquidia will post -1.51 earnings per share for the current year.
Insider Buying and Selling at Liquidia
In related news, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at $3,597,287.84. This trade represents a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Russell Schundler sold 5,964 shares of the firm's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the completion of the sale, the general counsel now directly owns 570,301 shares in the company, valued at approximately $7,738,984.57. This represents a 1.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,138 shares of company stock valued at $450,233 in the last ninety days. 30.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Liquidia
A number of hedge funds have recently made changes to their positions in LQDA. LM Advisors LLC bought a new stake in shares of Liquidia during the fourth quarter worth $25,948,000. Invesco Ltd. grew its position in Liquidia by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after acquiring an additional 674,940 shares during the last quarter. Janus Henderson Group PLC grew its position in Liquidia by 1,484.5% during the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock worth $6,293,000 after acquiring an additional 501,752 shares during the last quarter. Mirabella Financial Services LLP bought a new position in Liquidia in the fourth quarter valued at about $5,880,000. Finally, Eversept Partners LP boosted its stake in shares of Liquidia by 314.1% during the fourth quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Articles
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
